JOINT SESSION of the ESR and EORTC

ESR/EORTC - Advanced imaging for stratifying treatment in oligometastatic prostate cancer

Lectures

1
ESR/EORTC_1 - Whole-body MRI: is it ready for prime time to detect oligometastatic prostate cancer?

ESR/EORTC_1 - Whole-body MRI: is it ready for prime time to detect oligometastatic prostate cancer?

28:00Frederik de Keyzer, Leuven / BE

Learning Objectives
1. To learn about whole-body MRI: how to optimise the technique.
2. To appreciate the technical challenges and limitations of the technique in prostate cancer patients.
3. To understand how the output may be quantified and assessed.

2
ESR/EORTC_2 - Molecular imaging for directing and delivering therapy in oligometastatic prostate cancer

ESR/EORTC_2 - Molecular imaging for directing and delivering therapy in oligometastatic prostate cancer

20:22Daniela Oprea-Lager, Amsterdam / NL

Learning Objectives
1. To learn about targeted imaging and radionuclide therapy in oligometastatic prostate cancer.
2. To appreciate how molecular imaging may be used to stratify therapy.
3. To understand how to devise trials that establish an evidence-based use of modern imaging techniques.

ESR/EORTC-1
Prostate cancer: managing the oligometastatic patient
Learning Objectives
1. To learn about the classification of oligometastatic prostate cancer. 2. To appreciate the local and systemic management options for patients with oligometastatic prostate cancer. 3. To understand the impact on the outcome by stratifying patients for treatment.
ESR/EORTC-2
Whole-body MRI: is it ready for prime time to detect oligometastatic prostate cancer?
Learning Objectives
1. To learn about whole-body MRI: how to optimise the technique. 2. To appreciate the technical challenges and limitations of the technique in prostate cancer patients. 3. To understand how the output may be quantified and assessed.
ESR/EORTC-3
Molecular imaging for directing and delivering therapy in oligometastatic prostate cancer
Learning Objectives
1. To learn about targeted imaging and radionuclide therapy in oligometastatic prostate cancer. 2. To appreciate how molecular imaging may be used to stratify therapy. 3. To understand how to devise trials that establish an evidence-based use of modern imaging techniques.

PEP Subscription Required

This course is only accessible for ESR Premium Education Package subscribers.